Literature DB >> 23543139

Treatment outcomes according to neuropathic bladder sphincter dysfunction type after treatment of oxybutynin chloride in children with myelodysplasia.

Minki Baek1, Jung Yoon Kang, Jeongyun Jeong, Dae Kyung Kim, Kwang Myung Kim.   

Abstract

PURPOSE: We investigated the treatment outcomes according to neuropathic bladder sphincter dysfunction (NBSD) type after oral oxybutynin (OBT) treatment in children with NBSD caused by myelodysplasia.
METHODS: Among 334 pediatric patients who were diagnosed with NBSD caused by myelodysplasia, only children treated with oral OBT for more than 1 year with pre- and post-treatment urodynamic studies and dimercaptosuccinic acid (DMSA) were retrospectively reviewed. We compared pre- and post-treatment urodynamic parameters including maximum cystometric capacity (MCC), MCC/estimated bladder capacity (EBC), and compliance by NBSD type in children. We also compared renal scarring on pre- and post-treatment DMSA by NBSD type in children.
RESULTS: Our study population was comprised of 81 children (45 boys and 36 girls), with a mean age of 4.2 ± 3.4 years. The mean follow-up duration was 4.5 (range 1.0-15.1) years. After OBT treatment, MCC was increased significantly in all types of NBSD from 110.3 ± 62.2 to 202.3 ± 103.9 ml (p < 0.05), compliance was significantly improved from 6.4 ± 6.1 to 11.1 ± 9.6 ml/cmH2O (p < 0.05), but MCC/EBC was slightly decreased from 75.2 ± 46.9 to 69.8 ± 33.3 % (p = 0.40). Sub-analyzed by NBSD type, the pre-treatment compliance of children with acontractile detrusor with spastic sphincter (n = 16) was markedly decreased compared with other types of NBSD. Acontractile detrusor with spastic sphincter demonstrated the worst renal deterioration on DMSA.
CONCLUSIONS: Although increases in MCC/EBC were limited, oral OBT treatment markedly improved MCC and compliance in all NBSD types. Children who had acontractile detrusor with spastic sphincter had a relatively high probability of renal deterioration and required specific attention.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23543139     DOI: 10.1007/s11255-013-0423-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  22 in total

1.  Prospective open label study of solifenacin for overactive bladder in children.

Authors:  Stéphane Bolduc; Katherine Moore; Geneviève Nadeau; Sylvie Lebel; Pascale Lamontagne; Micheline Hamel
Journal:  J Urol       Date:  2010-08-21       Impact factor: 7.450

2.  The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children's Continence Society.

Authors:  Tryggve Nevéus; Alexander von Gontard; Piet Hoebeke; Kelm Hjälmås; Stuart Bauer; Wendy Bower; Troels Munch Jørgensen; Søren Rittig; Johan Vande Walle; Chung-Kwong Yeung; Jens Christian Djurhuus
Journal:  J Urol       Date:  2006-07       Impact factor: 7.450

3.  Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.

Authors:  Heinrich Schulte-Baukloh; Gerd Mürtz; Thomas Henne; Theodor Michael; Kurt Miller; Helmut H Knispel
Journal:  BJU Int       Date:  2006-02       Impact factor: 5.588

4.  Improved bladder function after prophylactic treatment of the high risk neurogenic bladder in newborns with myelomentingocele.

Authors:  M Kaefer; A Pabby; M Kelly; M Darbey; S B Bauer
Journal:  J Urol       Date:  1999-09       Impact factor: 7.450

Review 5.  Oxybutynin in detrusor overactivity.

Authors:  Ananias Diokno; Michael Ingber
Journal:  Urol Clin North Am       Date:  2006-11       Impact factor: 2.241

Review 6.  Neurogenic bladder dysfunction in children: review of pathophysiology and current management.

Authors:  E T Fernandes; Y Reinberg; R Vernier; R Gonzalez
Journal:  J Pediatr       Date:  1994-01       Impact factor: 4.406

7.  Treatment of infants with neurogenic bladder dysfunction using anticholinergic drugs and intermittent catheterisation.

Authors:  L S Baskin; B A Kogan; F Benard
Journal:  Br J Urol       Date:  1990-11

8.  Early start to therapy preserves kidney function in spina bifida patients.

Authors:  Pieter Dik; Aart J Klijn; Jan D van Gool; Catherine C E de Jong-de Vos van Steenwijk; Tom P V M de Jong
Journal:  Eur Urol       Date:  2006-01-19       Impact factor: 20.096

Review 9.  Initial urologic management of myelomeningocele.

Authors:  Warren T Snodgrass; Richard Adams
Journal:  Urol Clin North Am       Date:  2004-08       Impact factor: 2.241

10.  Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study.

Authors:  Helmut Madersbacher; Gerd Mürtz; Schahnaz Alloussi; Burghard Domurath; Thomas Henne; Iris Körner; Andreas Niedeggen; Joseph Nounla; Jürgen Pannek; Heinrich Schulte-Baukloh; Daniela Schultz-Lampel; Paul Bock; Gerhard Strugala
Journal:  BJU Int       Date:  2008-10-24       Impact factor: 5.588

View more
  2 in total

Review 1.  Pharmacotherapy for Pediatric Neurogenic Bladder.

Authors:  Paweł Kroll
Journal:  Paediatr Drugs       Date:  2017-10       Impact factor: 3.022

2.  Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open-label, phase 3, dose-titration study.

Authors:  Małgorzata Baka-Ostrowska; David T Bolong; Cristian Persu; Camilla Tøndel; Achim Steup; Christopher Lademacher; Nancy Martin
Journal:  Neurourol Urodyn       Date:  2021-05-31       Impact factor: 2.696

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.